News
GNPX
0.7380
+1.08%
0.0079
Genprex Advances Cancer Trials and Diabetes Therapy
TipRanks · 1d ago
Weekly Report: what happened at GNPX last week (0106-0110)?
Weekly Report · 2d ago
Weekly Report: what happened at GNPX last week (1230-0103)?
Weekly Report · 01/06 11:58
Weekly Report: what happened at GNPX last week (1223-1227)?
Weekly Report · 12/30/2024 11:50
Weekly Report: what happened at GNPX last week (1216-1220)?
Weekly Report · 12/23/2024 11:58
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/19/2024 17:01
Genprex receives Safety Review Committee approval to advance Acclaim-3 trial
TipRanks · 12/16/2024 14:20
GENPREX INC: RESULTS FROM PHASE 1 DOSE ESCALATION DEMONSTRATE FAVORABLE SAFETY PROFILE OF REQORSA AND TECENTRIQ IN ES-SCLC PATIENTS
Reuters · 12/16/2024 14:15
Weekly Report: what happened at GNPX last week (1209-1213)?
Weekly Report · 12/16/2024 11:59
Weekly Report: what happened at GNPX last week (1202-1206)?
Weekly Report · 12/09/2024 11:58
Weekly Report: what happened at GNPX last week (1125-1129)?
Weekly Report · 12/02/2024 11:58
Weekly Report: what happened at GNPX last week (1118-1122)?
Weekly Report · 11/25/2024 11:48
Genprex signs exclusive license agreement with University of Michigan
TipRanks · 11/20/2024 14:37
GENPREX INC - RECEIVES NASDAQ NOTICE FOR NON-COMPLIANCE WITH EQUITY REQUIREMENT
Reuters · 11/19/2024 22:17
Weekly Report: what happened at GNPX last week (1111-1115)?
Weekly Report · 11/18/2024 11:44
Based on the provided financial report article, the title of the article is likely: "Genprex, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2024" This title is inferred from the information provided, which includes the company name, the reporting period, and the type of financial report (10-Q).
Press release · 11/13/2024 21:52
Weekly Report: what happened at GNPX last week (1104-1108)?
Weekly Report · 11/11/2024 12:01
Genprex to present positive preclinical data from Reqorsa Gene Therapy study
TipRanks · 11/05/2024 14:35
GENPREX INC: REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Reuters · 11/05/2024 14:31
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Benzinga · 11/04/2024 16:05
More
Webull provides a variety of real-time GNPX stock news. You can receive the latest news about Genprex Inc through multiple platforms. This information may help you make smarter investment decisions.
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.